OsteoporeASX:OSX Current Ratio is 0.85 as of Dec. 2025, which is 70% below its 10-year median of 2.86. The stock has 7 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Osteopore ranks worse than 90.52% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Osteopore's current ratio for the quarter that ended in Dec. 2025 was 0.85.
Osteopore has a current ratio of 0.85. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Osteopore has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Osteopore's Current Ratio or its related term are showing as below:
ASX:OSX'
s Current Ratio Range Over the Past 10 Years
Min: 0.85 Med: 2.86 Max: 8.08
Current: 0.85
During the past 8 years, Osteopore's highest Current Ratio was 8.08. The lowest was 0.85. And the median was 2.86.
ASX:OSX's Current Ratio is ranked worse than 90.52% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs ASX:OSX: 0.85
Osteopore (ASX:OSX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Osteopore Current Ratio Related Terms
Osteopore Current Ratio Historical Data
* Premium members only.
The historical data trend for Osteopore's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OSX vs ISRG, BDX, MDLN: Current Ratio Comparison
For the Medical Instruments & Supplies subindustry, Osteopore's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Osteopore Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Osteopore's Current Ratio distribution charts can be found below:
* The bar in red indicates where Osteopore's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Osteopore (ASX:OSX) has a Current Ratio of 0.85 as of Dec. 2025. This is 70% below median its historical median of 2.86. Over the past decade, Osteopore's Current Ratio has ranged from 0.85 to 8.08. According to the industry distribution chart, Osteopore ranks #773 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 90.5%.
Is Osteopore's Current Ratio too high?
Osteopore's current Current Ratio of 0.85 is 70% below median its 10-year median of 2.86. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 8.08. The Medical Devices & Instruments industry median Current Ratio is 2.49. Osteopore's value of 0.85 is 65.8% below this industry median. Based on the distribution chart, Osteopore ranks #773 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Osteopore's Current Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Osteopore ranks #773 out of 854 companies for Current Ratio. This places Osteopore in the lower half of its industry. The industry median Current Ratio is 2.49. Osteopore's value of 0.85 is 65.8% below this benchmark. Historically, Osteopore's own Current Ratio has ranged from 0.85 to 8.08 over the past decade. While the company's 10-year median is 2.86 vs. the industry median of 2.49, Osteopore has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Osteopore's current Current Ratio of 0.85 is 65.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Osteopore's current Current Ratio is 0.85, which is 70% below median its own 10-year median of 2.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 80% below its estimated fair value. The current Current Ratio is 0.85, which is 70% below median its 10-year median of 2.86 and 65.8% below the Medical Devices & Instruments industry median of 2.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current Current Ratio is 0.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSX has been successfully added to your 